scholarly journals Receptor for advanced glycation end products mediates meningitis‐triggered amyloid‐β accumulation and cognitive impairment

2020 ◽  
Vol 16 (S3) ◽  
Author(s):  
Tatiana Barichello ◽  
Jaqueline S Generoso ◽  
Vijayasree V Giridharan ◽  
Allan Collodel ◽  
Diogo Dominguini ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Advanced Glycation End Products ◽  
Amyloid Β ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

scholarly journals Receptor for advanced glycation end products mediates sepsis-triggered amyloid-β accumulation, Tau phosphorylation, and cognitive impairment

2017 ◽  
Vol 293 (1) ◽  
pp. 226-244 ◽  
Author(s):  
Juciano Gasparotto ◽  
Carolina S. Girardi ◽  
Nauana Somensi ◽  
Camila T. Ribeiro ◽  
José C. F. Moreira ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Advanced Glycation End Products ◽  
Amyloid Β ◽  
Tau Phosphorylation ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

Levels of Receptor for Advanced Glycation End Products and Glyoxalase-1 in the Total Circulating Extracellular Vesicles from Mild Cognitive Impairment and Different Stages of Alzheimer’s Disease Patients

2021 ◽  
pp. 1-11
Author(s):  
Mohamed Haddad ◽  
Morgane Perrotte ◽  
Mohamed Raâfet Ben Khedher ◽  
Elise Madec ◽  
Aurelie Lepage ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Extracellular Vesicles ◽  
Advanced Glycation End Products ◽  
Neuronal Cells ◽  
Advanced Glycation ◽  
Glyoxalase 1 ◽  
Glycation End Products ◽  
End Products

Background: Growing evidence supports that receptor for advanced glycation end products (RAGE) and glyoxalase-1 (GLO-1) are implicated in the pathophysiology of Alzheimer’s disease (AD). Extracellular vesicles (EVs) are nanovesicles secreted by almost all cell types, contribute to cellular communication, and are implicated in AD pathology. Recently, EVs are considered as promising tools to identify reliable biomarkers in AD. Objective: The aim of our study was to determine the levels of RAGE and GLO-1 in circulating EVs from mild cognitive impairment (MCI) and AD patients and to analyze their correlation with the clinical Mini-Mental State Examination and Montreal Cognitive Assessment scores. We have studied the possibility that neuronal cells could release and transfer GLO-1 through EVs. Methods: RAGE and GLO-1 levels were measured in circulating EVs, respectively, by Luminex assay and western blot. Released-EVs from SK-N-SH neuronal cells were isolated and GLO-1 levels were determined by western bot. Results: Our data showed higher levels of RAGE in EVs from late AD patients while GLO-1 levels in EVs from early AD were lower as compared to control and MCI patients. Interestingly, levels of RAGE and GLO-1 in EVs were correlated with the cognitive scores regardless of age. For the first time, we demonstrated that GLO-1 was released from neuronal cells through EVs. Conclusion: Although more samples will be needed, our preliminary results support the use of peripheral EVs cargo as new tools for the discovery of peripheral AD biomarkers.

scholarly journals Advanced glycation end products and cognitive impairment in schizophrenia

PLoS ONE ◽  
2021 ◽  
Vol 16 (5) ◽  
pp. e0251283
Author(s):  
Akiko Kobori ◽  
Mitsuhiro Miyashita ◽  
Yasuhiro Miyano ◽  
Kazuhiro Suzuki ◽  
Kazuya Toriumi ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Advanced Glycation End Products ◽  
Processing Speed ◽  
Wisconsin Card Sorting Test ◽  
Cognitive Domain ◽  
Psychotic Symptoms ◽  
Advanced Glycation ◽  
Adult Intelligence Scale ◽  
Glycation End Products ◽  
End Products

Advanced glycation end products play a key role in the pathophysiology of schizophrenia. Cognitive impairment is one of the central features of schizophrenia; however, the association between advanced glycation end products and cognitive impairment remains unknown. This study investigated whether advanced glycation end products affect the cognitive domain in patients with schizophrenia. A total of 58 patients with chronic schizophrenia were included in this cross-sectional study. Plasma advanced glycation end products were measured using high-performance liquid chromatography (HPLC). Neuropsychological and cognitive functions were assessed using the Wechsler Adult Intelligence Scale, Third Version, and the Wisconsin Card Sorting Test Keio-FS version. Multiple regression analysis adjusted for age, sex, body mass index, educational years, daily dose of antipsychotics, and psychotic symptoms revealed that processing speed was significantly associated with plasma pentosidine, a representative advanced glycation end product (standardized β = -0.425; p = 0.009). Processing speed is the cognitive domain affected by advanced glycation end products. Considering preceding evidence that impaired processing speed is related to poor functional outcome, interventions targeted at reducing advanced glycation end products may contribute to promoting recovery of patients with schizophrenia as well as cognitive function improvement.

Sign in / Sign up

Export Citation Format

Share Document